Aug 24, 2026 08:00AM

Jul 15, 2026 01:29PM

Jul 15, 2026 10:18AM

Jul 15, 2026 09:51AM

Jul 15, 2026 09:21AM

Jul 14, 2026 11:15AM

Jul 13, 2026 05:37PM FDA approves Leqembi Iqlik subcutaneous injection for Alzheimer's

Jul 13, 2026 05:36PM

Jul 13, 2026 04:00AM

Jul 12, 2026 11:15AM

Jun 29, 2026 07:30AM

May 21, 2026 10:23AM

May 20, 2026 08:08AM

Apr 21, 2026 08:37AM Merck and Eisai report failed kidney cancer drug trial results

Apr 21, 2026 06:52AM

Apr 9, 2026 08:00AM

Mar 27, 2026 08:50AM

Mar 27, 2026 06:14AM

Mar 27, 2026 04:19AM

Mar 22, 2026 09:19PM

Mar 20, 2026 12:13PM LEQEMBI shows high treatment persistence in real-world study

Mar 20, 2026 12:05PM

Mar 10, 2026 10:07PM

Mar 10, 2026 07:30PM

Mar 1, 2026 06:49PM

Feb 9, 2026 10:34PM

Feb 6, 2026 01:04AM

Feb 5, 2026 08:31PM Eisai and Henlius Enter into Exclusive Commercial License Agreement for Anti-PD-1 Antibody Serplulimab in Japan

Jan 25, 2026 11:52PM

Jan 25, 2026 08:37PM

Jan 25, 2026 06:30PM

Jan 25, 2026 06:30PM

Jan 12, 2026 06:50PM

Jan 5, 2026 07:43PM

Dec 3, 2025 06:10PM Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI® (lecanemab-irmb) Maintenance Treatment in Early Alzheimer's Disease at the Clinical Trials on Alzheimer's Disease (CTAD) Con

Dec 2, 2025 04:40PM

Dec 1, 2025 07:35PM

Nov 26, 2025 06:03AM

Nov 26, 2025 04:42AM

Nov 25, 2025 07:31AM

Nov 25, 2025 07:30AM

Nov 18, 2025 08:00AM Eisai to Present Data on Lecanemab Continued Treatment, Subcutaneous Initiation Dosing, and Real-World Experience at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference

Nov 17, 2025 07:08AM

Nov 3, 2025 08:08AM

Oct 27, 2025 12:23AM

Oct 14, 2025 03:54AM

Oct 13, 2025 07:30PM

Oct 6, 2025 04:30PM

Oct 3, 2025 04:01AM Eisai Highlights Breadth of Oncology Research at ESMO 2025

Oct 2, 2025 08:08AM

331,677 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All